A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 50
- Registration Number
- NCT07020988
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 32
- Registration Number
- NCT06970301
- Locations
- 🇺🇸
Up0135 1001, Glendale, California, United States
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 15
- Registration Number
- NCT06961747
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT06921850
- Locations
- 🇺🇸
Hs0006 50708, Roseville, California, United States
🇺🇸Hs0006 50712, Franklin, Kentucky, United States
🇺🇸Hs0006 50178, Clarkston, Michigan, United States
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Phase 1
Recruiting
- Conditions
- Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAxial SpondyloarthritisHidradenitis Suppurativa
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 20
- Registration Number
- NCT06888193
- Locations
- 🇨🇦
Up0122 202, Calgary, Canada
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 15
- Registration Number
- NCT06720714
- Locations
- 🇺🇸
UP0141 2, San Antonio, Texas, United States
🇺🇸UP0141 1, Salt Lake City, Utah, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 32
- Registration Number
- NCT06716879
- Locations
- 🇺🇸
UP0142 1, Anaheim, California, United States
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Phase 3
Recruiting
- Conditions
- Enthesitis-related ArthritisJuvenile Psoriatic Arthritis
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT06668181
- Locations
- 🇨🇦
Ja0005 50646, Calgary, Canada
🇨🇦Ja0005 50645, Saskatoon, Canada
🇫🇷Ja0005 40777, Indre-et-Loire, France
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Phase 3
Recruiting
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 550
- Registration Number
- NCT06624228
- Locations
- 🇺🇸
Pa0016 50027, Seattle, Washington, United States
🇬🇧Pa0016 40113, London, United Kingdom
🇬🇧Pa0016 40825, Wolverhampton, United Kingdom
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Phase 3
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: DZPOther: Placebo
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 450
- Registration Number
- NCT06617325
- Locations
- 🇺🇸
Sl0044 50264, Manhasset, New York, United States
🇺🇸Sl0044 50077, New York, New York, United States
🇺🇸Sl0044 50238, Charlotte, North Carolina, United States